AR117809A2 - NEWCASTLE DISEASE VIRUS AND ITS USES - Google Patents

NEWCASTLE DISEASE VIRUS AND ITS USES

Info

Publication number
AR117809A2
AR117809A2 ARP200100081A ARP200100081A AR117809A2 AR 117809 A2 AR117809 A2 AR 117809A2 AR P200100081 A ARP200100081 A AR P200100081A AR P200100081 A ARP200100081 A AR P200100081A AR 117809 A2 AR117809 A2 AR 117809A2
Authority
AR
Argentina
Prior art keywords
newcastle disease
chimeric
disease virus
antagonist
ligand
Prior art date
Application number
ARP200100081A
Other languages
Spanish (es)
Original Assignee
Icahn School Med Mount Sinai
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme filed Critical Icahn School Med Mount Sinai
Publication of AR117809A2 publication Critical patent/AR117809A2/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se describen virus quiméricos de la enfermedad de Newcastle que comprenden un genoma empaquetado que comprende un transgén que codifica interleucina-12. Los virus quiméricos de la enfermedad de Newcastle y las composiciones de los mismos son útiles en combinación con un antagonista de la proteína 1 de la muerte celular programada (“PD-1”) o un ligando de la misma en el tratamiento del cáncer. En particular, en el presente documento se describen procedimientos para tratar el cáncer que comprenden administrar los virus quiméricos de la enfermedad de Newcastle en combinación con un antagonista de PD-1 o un ligando de la misma, en el que el virus quimérico de la enfermedad de Newcastle comprende un genoma empaquetado que comprende un transgén que codifica interleucina-12.Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. Chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 ("PD-1") or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer that comprise administering the chimeric Newcastle disease viruses in combination with a PD-1 antagonist or ligand thereof, wherein the chimeric disease virus Newcastle comprises a packaged genome comprising a transgene encoding interleukin-12.

ARP200100081A 2017-05-12 2020-01-13 NEWCASTLE DISEASE VIRUS AND ITS USES AR117809A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762505759P 2017-05-12 2017-05-12

Publications (1)

Publication Number Publication Date
AR117809A2 true AR117809A2 (en) 2021-08-25

Family

ID=69232892

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP180101258A AR112906A1 (en) 2017-05-12 2018-05-11 NEWCASTLE DISEASE VIRUS AND ITS USES
ARP200100081A AR117809A2 (en) 2017-05-12 2020-01-13 NEWCASTLE DISEASE VIRUS AND ITS USES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP180101258A AR112906A1 (en) 2017-05-12 2018-05-11 NEWCASTLE DISEASE VIRUS AND ITS USES

Country Status (1)

Country Link
AR (2) AR112906A1 (en)

Also Published As

Publication number Publication date
AR112906A1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
ECSP19080602A (en) NEWCASTLE DISEASE VIRUS AND USES OF THE SAME
CO2020003478A2 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and their uses
CO2020015255A2 (en) Methods and compositions for treating cancer
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CL2020001575A1 (en) Anti-trem2 antibodies and related methods.
CL2017002731A1 (en) Oncolytic adenovirus encoding a b7 protein
CO2019011450A2 (en) Tissue selective transgene expression
AR108630A1 (en) GENETICALLY MODIFIED VACCINIA VIRUSES
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
ECSP20046463A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING TISSUES WITH ACIDIC OR HYPOXIC DISEASES
BR112019001737A2 (en) pten-long expression with oncolytic viruses
UY35964A (en) HUMAN ANTIBODIES FOR PD? 1
EA201991622A1 (en) COMPLEX THERAPY FOR TREATMENT OF CANCER
EA202090124A1 (en) ADENOVIRUS ARMED WITH A BISPECIFIC T-CELL RECRUITER (BITE)
BR112019017403A2 (en) compositions and methods for the treatment of cancer
CY1123216T1 (en) GLS1 INHIBITORS FOR THE TREATMENT OF DISEASE
BR112017014361A2 (en) methods for perfecting cell therapy
CO2019003865A2 (en) Therapeutic protein
BR112018009745A2 (en) heterocyclic compounds for the treatment of disease
CO2020013050A2 (en) Human kinureninase enzymes and their uses
BR112022001881A2 (en) Genetically manipulated oncolytic vaccinia virus and methods of using it
AR117809A2 (en) NEWCASTLE DISEASE VIRUS AND ITS USES
EA201890623A1 (en) RATIONAL COMBINED THERAPY FOR CANCER TREATMENT
EA202190226A1 (en) METHODS FOR TREATMENT OF HFpEF USING DAPAGLIFLOSIN AND COMPOSITIONS CONTAINING IT
EA201992687A1 (en) NEWcastle Disease VIRUSES AND THEIR APPLICATION